Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.
H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 5, 14, 1, 30 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Akshaya Bio Inc
Altimmune Inc
Antigen Express Inc
Aphios Corp
BioDiem Ltd
BiondVax Pharmaceuticals Ltd
CEL-SCI Corp
Cocrystal Pharma Inc
Curevac AG
Fab'entech SA
Gemmus Pharma Inc
GlaxoSmithKline Plc
Hemispherx Biopharma Inc
iBio Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Lakewood-Amedex Inc
Medicago Inc
Medigen Vaccine Biologics Corp
Microbiotix Inc
NanoBio Corp
Nanotherapeutics Inc
NanoViricides Inc
NewLink Genetics Corp
OPKO Health Inc
PaxVax Inc
PeptiDream Inc
Shionogi & Co Ltd
Takeda Pharmaceutical Company Ltd
TechnoVax Inc
TGV-Inhalonix Inc
Vaxart Inc
Vaxine Pty Ltd
VaxInnate Corp
Visterra Inc
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Influenza A Virus, H5N1 Subtype Infections – Overview 8
Influenza A Virus, H5N1 Subtype Infections – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Influenza A Virus, H5N1 Subtype Infections – Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Influenza A Virus, H5N1 Subtype Infections – Companies Involved in Therapeutics Development 28
Akshaya Bio Inc 28
Altimmune Inc 28
Antigen Express Inc 29
Aphios Corp 29
BioDiem Ltd 30
BiondVax Pharmaceuticals Ltd 30
CEL-SCI Corp 31
Cocrystal Pharma Inc 31
Curevac AG 32
Fab'entech SA 32
Gemmus Pharma Inc 33
GlaxoSmithKline Plc 33
Hemispherx Biopharma Inc 34
iBio Inc 34
Inovio Pharmaceuticals Inc 35
Johnson & Johnson 35
Kineta Inc 36
Lakewood-Amedex Inc 36
Medicago Inc 37
Medigen Vaccine Biologics Corp 37
Microbiotix Inc 38
NanoBio Corp 38
Nanotherapeutics Inc 39
NanoViricides Inc 39
NewLink Genetics Corp 40
OPKO Health Inc 40
PaxVax Inc 41
PeptiDream Inc 41
Shionogi & Co Ltd 42
Takeda Pharmaceutical Company Ltd 43
TechnoVax Inc 43
TGV-Inhalonix Inc 44
Vaxart Inc 44
Vaxine Pty Ltd 45
VaxInnate Corp 45
Visterra Inc 46
Influenza A Virus, H5N1 Subtype Infections – Drug Profiles 47
AE-AI vaccine – Drug Profile 47
Alferon LDO – Drug Profile 48
APP-0205 – Drug Profile 50
APP-309 – Drug Profile 51
AT-301 – Drug Profile 52
CC-42344 – Drug Profile 53
CEL-1000 – Drug Profile 54
CHOS-05 – Drug Profile 56
DPC-005 – Drug Profile 57
FBF-001 – Drug Profile 58
Gamma-Flu – Drug Profile 59
GP-1001 – Drug Profile 60
GP-1002 – Drug Profile 61
GP-1681 – Drug Profile 62
GREFLU/VIE – Drug Profile 64
HAI-05 – Drug Profile 65
HB-36.6 – Drug Profile 67
Influ-nRNA – Drug Profile 68
influenza [strain A/H5N1] (split virion) vaccine – Drug Profile 69
influenza [strain A/H5N1] (virus like particle) vaccine 2 – Drug Profile 70
influenza [strain A/H5N1] vaccine – Drug Profile 73
influenza [strain A/H5N1] vaccine – Drug Profile 74
influenza [strain A/H5N1] vaccine – Drug Profile 75
influenza [strain A/H5N1] vaccine – Drug Profile 77
influenza [strain A/H5N1] vaccine – Drug Profile 78
influenza [strain A/H5N1] vaccine – Drug Profile 79
influenza [strain A/H5N1] vaccine – Drug Profile 80
influenza [strain A/H5N1] vaccine – Drug Profile 81
influenza [strain A/H5N1] vaccine – Drug Profile 82
influenza [strain A/H5N1] vaccine 2 – Drug Profile 83
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine – Drug Profile 84
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine – Drug Profile 85
influenza [strains A/H1N1 + A/H5N1] vaccine – Drug Profile 86
influenza [strains A/H5N1 + A/H1N1] vaccine – Drug Profile 87
influenza [strains A/H5N1 + A/H7N2 + A/H9N2 + A/H7N3 + A/ H5N2] (virus like particle) vaccine – Drug Profile 88
influenza vaccine – Drug Profile 89
INO-3510 – Drug Profile 91
JNJ-3872 – Drug Profile 93
KD-295 – Drug Profile 96
KIN-1148 – Drug Profile 98
Lalistat – Drug Profile 100
M-001 – Drug Profile 101
MBX-2329 – Drug Profile 107
MBX-2546 – Drug Profile 108
Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection – Drug Profile 109
Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections – Drug Profile 110
MV-4 – Drug Profile 111
Nasovax – Drug Profile 112
NVINF-1 – Drug Profile 114
NVINF-2 – Drug Profile 119
OrniFlu – Drug Profile 122
PD-001 – Drug Profile 123
Peptides for Influenza Infections – Drug Profile 124
PNSIA-28 – Drug Profile 125
PNSIA-49 – Drug Profile 126
PXVX-0103 – Drug Profile 127
rintatolimod – Drug Profile 129
S-033188 – Drug Profile 139
Small Molecules for Influenza A Virus H1N1 and H5N1 Infections – Drug Profile 141
Small Molecules to Activate Sirtuin for Influenza – Drug Profile 142
Synthetic Peptides for Influenza, HSV and HIV Infections – Drug Profile 143
Synthetic Peptides for Viral Infections – Drug Profile 144
TVX-003 – Drug Profile 145
VAX-161C – Drug Profile 146
VGX-3400X – Drug Profile 147
VH-244 – Drug Profile 149
VIS-410 – Drug Profile 150
Influenza A Virus, H5N1 Subtype Infections – Dormant Projects 153
Influenza A Virus, H5N1 Subtype Infections – Discontinued Products 156
Influenza A Virus, H5N1 Subtype Infections – Product Development Milestones 157
Featured News & Press Releases 157
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 167
Disclaimer 168
List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Akshaya Bio Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Altimmune Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Antigen Express Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Aphios Corp, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by BioDiem Ltd, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by CEL-SCI Corp, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Curevac AG, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Fab'entech SA, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Gemmus Pharma Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by GlaxoSmithKline Plc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Hemispherx Biopharma Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by iBio Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Johnson & Johnson, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Kineta Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Lakewood-Amedex Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Medicago Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Medigen Vaccine Biologics Corp, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Microbiotix Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by NanoBio Corp, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Nanotherapeutics Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by NanoViricides Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by NewLink Genetics Corp, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by OPKO Health Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by PaxVax Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by PeptiDream Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Shionogi & Co Ltd, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by TechnoVax Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by TGV-Inhalonix Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Vaxart Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Vaxine Pty Ltd, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by VaxInnate Corp, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Pipeline by Visterra Inc, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H1 2017
Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H1 2017 (Contd..1), H1 2017
Influenza A Virus, H5N1 Subtype Infections – Dormant Projects, H1 2017 (Contd..2), H1 2017
Influenza A Virus, H5N1 Subtype Infections – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
